Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	37.82	75.22	83.16	61.9	173.31	183.35
Short-Term Investments	214.38	217.26	365.54	455.42	283.99	644.56
Cash & Short-Term Investments	252.19	292.48	448.7	517.32	457.3	827.91
Cash Growth	-13.50%	-34.82%	-13.26%	13.12%	-44.76%	56.05%
Other Receivables	2.1	1.9	1.7	3.3	6	6.6
Receivables	2.1	1.9	1.7	3.3	6	6.6
Prepaid Expenses	6.43	9.01	8.72	8.2	8.02	10.62
Total Current Assets	260.72	303.39	459.12	528.82	471.32	845.13
Property, Plant & Equipment	116.83	131.26	163.18	196.43	181.02	160.14
Long-Term Investments	24.94	80.67	3.65	79.47	370.18	207.95
Other Long-Term Assets	37.28	33.39	16.9	16.86	16.11	14.62
Total Assets	439.77	548.71	642.84	821.58	1,039	1,228
Accounts Payable	3.7	5.39	5.9	13.89	10.26	10.39
Accrued Expenses	20.13	21.55	21.98	29.73	29.65	29.83
Current Portion of Leases	8.01	7.51	6.78	6	3.2	2.97
Current Unearned Revenue	-	-	0.09	0.1	0.42	38.99
Other Current Liabilities	-	1.07	2.34	4.02	4.65	12.13
Total Current Liabilities	31.83	35.52	37.08	53.73	48.17	94.32
Long-Term Leases	77.13	83.25	88.35	95.12	69.93	50.81
Other Long-Term Liabilities	10.88	7.76	5.18	5.85	4.13	3.08
Total Liabilities	124.44	126.53	130.6	154.7	122.23	148.21
Common Stock	0.22	0.21	0.17	0.14	0.14	0.14
Additional Paid-In Capital	2,287	2,242	2,075	1,912	1,822	1,726
Retained Earnings	-1,972	-1,820	-1,562	-1,235	-903.35	-646.34
Comprehensive Income & Other	0.24	-0.09	-0.96	-9.93	-2.57	0.27
Shareholders' Equity	315.33	422.18	512.23	666.88	916.41	1,080
Total Liabilities & Equity	439.77	548.71	642.84	821.58	1,039	1,228
Total Debt	85.14	90.76	95.12	101.12	73.13	53.78
Net Cash (Debt)	167.05	201.72	353.58	416.2	384.17	774.13
Net Cash Growth	-16.07%	-42.95%	-15.05%	8.34%	-50.37%	62.12%
Net Cash Per Share	0.77	1.04	2.25	2.91	2.83	6.43
Filing Date Shares Outstanding	224.73	217.26	169.09	144.5	142.75	140.65
Total Common Shares Outstanding	223.16	212.21	168.64	144.44	142.62	140.47
Working Capital	228.89	267.86	422.04	475.1	423.15	750.81
Book Value Per Share	1.41	1.99	3.04	4.62	6.43	7.69
Tangible Book Value	315.33	422.18	512.23	666.88	916.41	1,080
Tangible Book Value Per Share	1.41	1.99	3.04	4.62	6.43	7.69
Machinery	37.87	40.47	41.94	41.15	37.96	31.29
Construction In Progress	-	-	-	0.03	0.04	68.94
Leasehold Improvements	107.54	108.13	108.62	108.55	108.35	31.52

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q